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Abstract
Chronic ingestion of water containing inorganic arsenic (iAs) has been linked to a variety of
adverse health effects, including cancer, hypertension and diabetes. Current evidence suggests that
the toxic methylated trivalent metabolites of iAs, methylarsonous acid (MAs) and
dimethylarsinous acid (DMAsIII) play a key role in the etiology of these diseases. Both MAs and
DMAsIII have been detected in urine of subjects exposed to iAs. However, the rapid oxidation of
DMAsIII and, to a lesser extent, MAsIII in oxygen-rich environments leads to difficulties in the
analysis of these metabolites in samples of urine collected in population studies. Results of our
previous work indicate that MAsIII and DMAsIII are relatively stable in a reducing cellular
environment and can be quantified in cells and tissues. In the present study, we used the oxidation
state-specific hydride generation-cryotrapping-atomic absorption spectroscopy (HG-CT-AAS) to
examine the presence and stability of these trivalent metabolites in the liver of mice and in
UROtsa/F35 cells exposed to iAs. Tri- and pentavalent metabolites of iAs were analyzed directly
(without chemical extraction or digestion). Liver homogenates prepared in cold deionized water
and cell culture medium and lysates were stored at either 0 °C or −80 °C for up to 22 days. Both
MAsIII and DMAsIII were stable in homogenates stored at −80 °C. In contrast, DMAsIII in
homogenates stored at 0 °C began to oxidize to its pentavalent counterpart after 1 day; MAsIII
remained stable for at least 3 weeks under these conditions. MAsIII and DMAsIII generated in
UROtsa/F35 cultures were stable for 3 weeks when culture media and cell lysates were stored at
−80 °C. These results suggest that samples of cells and tissues represent suitable material for the
quantitative, oxidation state-specific analysis of As in laboratory and population studies examining
the metabolism or toxic effects of this metalloid.
†Electronic supplementary information (ESI) available: A scheme of the optimized HG-CT-AAS instrumentation and additional data
on stability of DMAsIII in cell lysates. See DOI: 10.1039/c1mt00095k
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Inorganic arsenic (iAs) is a natural, carcinogenic metalloid found in water sources
worldwide, most commonly as arsenite (iAsIII) and arsenate (iAsV).1 The ingestion of
drinking water containing high levels of iAs is associated with an array of adverse health
effects, including cancer of the skin, lungs, liver and urinary bladder.2 Non-neoplastic
effects of iAs exposure include vascular disease, hypertension, skin lesions and diabetes. 3–5
Chronic toxicity due to drinking water with high levels of iAs can lead to a collection of
these symptoms, known as arsenicosis.6 The United States Environmental Protection
Agency and World Health Organization lowered the safe level for As in drinking water from
50 to 10 ppb in response to evidence of iAs toxicity even at low exposure levels.7,8 For the
tens of millions of people chronically exposed to iAs, outcomes vary widely and depend not
only on the level of exposure but also on the inter-individual differences in As metabolism.
Exposure levels and the pattern of iAs metabolism are commonly assessed through analysis
of iAs metabolites in urine; however, concentrations of these metabolites in human tissues
are not well researched.
The metabolism of iAs in humans is mediated by arsenic (+3 oxidation state)
methyltransferase (AS3MT).9 The AS3MT-catalyzed and S-adenosylmethionine-dependent
methylation of iAs yields both trivalent and pentavalent methylated arsenicals, including
methylarsonic acid (MAsV), methylarsonous acid (MAsIII), dimethylarsinic acid (DMAsV)
and dimethylarsinous acid (DMAsIII).10,11 Several intronic and exonic polymorphisms have
been described for the human AS3MT gene, including Met287The (T → C), potentially
altering the rates and yields of iAs methylation and contributing to the inter-individual
differences in susceptibility to iAs toxicity.12,13
While the methylation of iAs is critical for its detoxification, recent evidence suggests that
methylated trivalent As metabolites (MAsIII and DMAsIII) generated in the course of iAs
metabolism in human cells and tissues are more cytotoxic and genotoxic than their
pentavalent counterparts or iAs species.14 MAsIII and DMAsIII are also potent enzyme
inhibitors, alter cell signalling pathways, and induce oxidative damage.15–17 Moreover,
these As metabolites have been shown to inhibit insulin signalling and insulin-stimulated
glucose uptake in cultured murine adipocytes, providing a potential mechanism for the
diabetogenic effects of iAs exposure.18,19
The analysis of iAs metabolites in human population studies has been typically limited to
urine. The half life of iAs in the human body measures in days. Thus, although urine is an
important source of information about exposure to iAs, the urinary metabolites reflect only
recent exposures.20 Furthermore, analysis of As species in urine of chronically exposed
individuals produces a wide range of responses, making it difficult to elucidate the
mechanisms responsible for iAs toxicity and the direct effects on target human tissues, such
as, skin, urinary bladder, lungs, and liver. Interestingly, in vivo studies indicate that urinary
excretion of iAs and its metabolites does not correspond to tissue distribution of these As
species.21,22 For example, in mice exposed to iAsV in drinking water the predominant
accumulation of MAs in the kidney and DMAs in the lungs has been reported.21,22
Furthermore, a study comparing human urinary metabolites of iAs to As species retained in
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bladder exfoliated cells found no correlation, suggesting that monitoring urine may not give
a clear idea of As species stored in specific tissues.23 Thus, identification and quantification
of iAs metabolites in human tissues, including the target organs, or in cells originating from
these tissues could provide important information about the risk associated with iAs
exposure and about the mechanism underlying the adverse effects of this exposure.
The oxidation state-specific speciation analysis of As in urine is complicated mainly by the
low stability of methylated trivalent arsenicals, particularly DMAsIII. DMAsIII can be
completely converted to DMAsV in several hours even in frozen urine; MAsIII can oxidize
in several months.24 However, the rate of oxidation varies and depends, in part, on
individual urine composition, further confusing the interpretation of the analytical data. To
date, no attempt has been made to characterize the stability of the methylated trivalent As
species in tissues and cells. Mammalian cells contain millimolar concentrations of a potent
low-molecular weight reductant, glutathione (GSH), which is known to bind trivalent
arsenicals, producing AsIII–thiol complexes.25 Thus, the binding to GSH or to protein thiols
is likely to protect the methylated trivalent arsenicals from oxidation and extend their
lifetime inside the cells.
The main objective of this study was to optimize the hydride generation-cryotrapping-
atomic absorption spectroscopy (HG-CT-AAS) system for analysis of tissues and cells and
to characterize the stability of trivalent arsenicals, particularly DMAsIII in these complex
biological matrices. Here we report, for the first time, that DMAsIII is relatively stable in
tissue homo-genates and cell lysates under conditions that are typically used for storage and
transport of biological samples collected in laboratory and population studies. We, therefore,
suggest that samples of the tissues targeted by iAs exposure or cells originated from these
tissues are used to obtain more complete information about the metabolism of iAs or about
the mechanisms of iAs toxicity in animals and humans.
Methods
Arsenicals
The following arsenicals were used for calibration and in cell culture experiments: sodium
arsenite (NaAsIIIO2) and sodium arsenate (Na2HAsVO4) (>99% pure) were purchased from
Sigma-Aldrich (St. Louis, MO). Methylarsonic acid, disodium salt (CH3AsVO(ONa)2), and
dimethylarsinic acid ((CH3)2AsVO(OH)) both better than 98% pure were purchased from
Chem Service (West Chester, PA). Oxomethyl-arsine (CH3AsO)4 which forms MAsIII in
aqueous solution was provided by Dr William Cullen (University of British Columbia,
Vancouver, Canada). The As content in each of the standards was determined by graphite
furnace-AAS.26
Mice and treatments
Twelve week-old C57BL/6 mice were obtained from Jackson Laboratory (Bar Harbor, ME,
USA) and housed in polycarbonate cages (2 per cage) with corn cob bedding at the
University of North Carolina Animal Facility (12 h light/dark cycle, 22 ± 1 °C and humidity
50 ± 10%), accredited by the American Association for Accreditation of Laboratory Animal
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Care. Mice were allowed free access to food (Lab Diet 5058, Nutrition International,
Brentwood, MO) and pure deionized water (DIW) or DIW containing iAsIII (50 mg As per
L, i.e. 50 ppm). Mice were euthanized by cervical dislocation. Freshly dissected mice livers
were processed as previously described.27 Liver homogenates were prepared in ice cold
DIW (10% w/v). All procedures involving mice were approved by the UNC Institutional
Animal Care and Use Committee.
Cultured cells and treatments
The SV-40 transformed human urothelial cell line, UROtsa, was obtained from Dr Unimye
(Department of Urology, West Virginia University). The UROtsa/F35 clonal cell line
expressing rat As3mt and capable of As methylation was previously generated from the
parental UROtsa cell line using a retroviral pLEGFP-Nl gene delivery system.28 In the
present study, UROtsa/F35 cells were cultured in MEM (Mediatech, Manassas, VA)
supplemented with 10% heat inactivated FBS (Gemini Bio-Products, Sacramento, CA), 50
U penicillin (Sigma) per mL and 50 µg streptomycin (Sigma) per mL. Cells were cultured in
6-well plates (Corning, Inc., Corning, NY) at 37 °C in a humidified incubator with a 95%
air/5% CO2 atmosphere. To generate DMAsIII, near confluent cells in 6-well plates were
incubated with MAsIII in 2 mL of MEM/well for varying lengths of time. After incubation,
media were aspirated into capped tubes, cells were lysed on ice in pre-chilled DIW for 20
minutes and harvested by scraping with a pipette tip to reduce transfer losses. In some
experiments, cells were lysed in 0.5% Triton X-100. Control, unexposed UROtsa/F35 cells
were used to establish the background levels of As species in the cell culture.
Depletion of intracellular GSH
In some experiments, the cultured UROtsa/F35 cells were treated with butathione
sulfoximine (BSO), the inhibitor of GSH synthesis. BSO was added to the culture medium
at a final concentration of 250 µM BSO for 24 hours. The GSH concentrations were
measured before and after BSO treatment in cell lysates prepared in 2% sulfosalicylic acid,
using a previously described enzymatic recycling assay.29
Speciation analysis of As by HG-CT-AAS
Arsenic species were analyzed by a semi-automated HG-CT-AAS using a AAnalyst 800
spectrometer (Perkin-Elmer, Norwalk, CT, USA) equipped with a multiple microflame
quartz tube atomizer (multiatomizer) and coupled to a cryotrap. The HG and CT steps were
controlled by a FIAS 400 flow injection accessory (Perkin-Elmer).26,30 Using this system,
arsines from trivalent arsenicals (iAsIII, MAsIII and DMAsIII) are generated directly at pH 6;
to generate arsines from both tri- and pentavalent arsenicals (iAsIII + V, MAsIII + V and
DMAsIII + V), the As V-standards and samples are pre-reduced with L-cysteine (EMD
Chemicals Inc., Gibbstown, NJ).26,30 The concentrations of iAsV, MAsV, and DMAsV are
then determined as a difference between AAS signals obtained for cysteine-treated and
untreated sample aliquots.
We have previously shown that the slopes of the calibration curves for the cysteine-treated
AsV-standards prepared in DIW are identical with the slopes of curves generated for the
trivalent arsenicals in the absence of cysteine.30 We have also shown that the slopes of the
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calibration curves for the cysteine-treated aqueous solutions of As standards do not
significantly differ from the slopes of curves prepared for liver homogenates spiked with
these standards and treated with cysteine.27 Therefore, calibration curves for quantification
of tri- and pentavalent As species in this study were generated using aqueous solutions of the
pentavalent standards (iAsV, MAsV, and DMAsV) treated with cysteine.
Acid digestion
To determine the recovery of As species during the direct analyses of mouse liver
homogenates, aliquots of the homogenates were acid digested using a MARS Microwave
Reaction System equipped with MarsXpress Temperature Control (CAM, Matthews, NC).
Here, 100 µL of 10% homogenate was mixed with 3 mL of 2 M ultrapure phosphoric acid
(EMD Chemicals, Inc.) and microwaved for 10 hours at 90 ± 4 °C. One millilitre of the
digestate was neutralized with 0.25 mL of 10 N NaOH to a final pH of ~6. Because this
digestion oxidizes all trivalent arsenicals to their pentavalent counterparts, the neutralized
digestates were treated with 2% cysteine for 1 hour prior to analysis.27
Statistical analysis
All statistical analyses were performed using GraphPad Instat software package (GraphPad
Software Inc., San Diego, CA). Linear regression and correlation analyses were employed to
characterize the calibration curves. ANOVA followed by Bonferroni’s multiple comparison
posttest was used to determine significant differences in As concentration between fresh,
immediately analyzed samples and each time point during the storage of samples at either 0
°C or −80 °C This test was also used to determine differences in DMAsIII present in cell
lysates after lysis with either DIW or 0.5% Triton X-100. Statistical significance was
considered at the level of p < 0.01.
Results and discussion
Speciation analysis of As in biological matrices
The growing number of reports on widespread exposures to iAs in drinking water has
triggered an intensive search for biomarkers that could serve as indicators of these exposures
or could predict the susceptibility of individuals to diseases associated with chronic toxicity
of iAs. For many years, the urinary concentrations of As species that originate from iAs
metabolism in human tissues have been used as the exposure indicators. In addition, the
composition of iAs metabolites in human urine (e.g., DMAs/MAs ratio) is believed to
provide information about the capacity of individuals to methylate and thus to detoxify
iAs.31,32 The attempts to determine concentrations of iAs metabolites, especially the toxic
MAsIII and DMAsIII in tissues, have been rare and suffered problems associated with the
lack of suitable analytical techniques and with low stability of these methylated trivalent
arsenicals.
We have shown that in rat liver cytosol large portions of iAs and its methylated metabolites
are bound to proteins.33 The binding of As species to proteins that has also been reported by
others34,35 makes it necessary to perform digestions or extraction when chromatographic
methods are used for speciation analysis of As in cells, tissues, or tissue fractions. However,
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both digestion and extraction can lead to oxidation or losses of the unstable and highly
reactive methylated AsIII species.36 Our previous work has provided strong evidence that, in
spite of their limited specificity, HG-based techniques coupled with a sensitive detector may
provide a unique tool for the detection and quantification of MAsIII and DMAsIII in the
biological matrices as complex as cultured cells or tissue.26,27,30,37 The present study
continues this work by examining stability of the methylated trivalent arsenicals in liver
homogenates and cell lysates using a HG-CT-AAS technique developed by our laboratories.
Optimization of HG-CT-AAS for analysis of slurries
The previously described HG-CT-AAS system was developed for analysis of solutions and
relatively simple liquid biological matrices.26,30 This system was optimized in the present
study for analysis of complex biological slurries, including tissue homogenates and crude
cell lysates (Fig. SI, ESI†). To avoid plugging of the FIAS 400 injection port with tissue and
cell fragments, the homogenates and cell lysates were introduced directly to the manifold.
The sample (typically 500 µL) was pipetted into a 1 mL pipette tip connected to the FIAS
400 peristaltic pump. From the pipette tip, the sample was pumped into the system followed
by 500 µL of DIW. The sample was then mixed with equal flows (2 mL min−1) of Tris-HCl
buffer (pH 6) and NaBH4 solutions prior to entering the reaction coil and the gas–liquid
separator. For drying of the gaseous phase prior to the cryotrapping stage, a cartridge filled
with NaOH pellets was included.38 The cryotrapping step and AAS detection were
performed without modifications as previously described.26
Further optimization focused on the pre-reduction with cysteine and on the components of
the HG mixture. Here, liver homogenate from a single mouse exposed to iAsIII (50 ppm As)
in drinking water was aliquoted, pre-treated with cysteine (0.5, 2 or 4%) for up to 80
minutes and analyzed directly by HG-CT-AAS. Results of the direct analysis suggest that
treatment with 0.5–2% cysteine for at least 20 minutes is optimal for generation of arsines
from all As species present in the homogenate (Fig. 1). It is unclear why the AAS signals
were lower for homogenate aliquots treated with 4% cysteine. It is possible that portions of
arsenicals in homogenates were reduced by high cysteine concentration to form volatile
arsines, thus decreasing the amounts of arsines generated during the HG step.
In the next step, AAS signals were tested in the reaction mixtures containing liver
homogenates treated for 1 hour with 2% cysteine and varied concentrations of Tris-HCl (pH
6) or NaBH4. For this test we pooled liver homogenates from several mice exposed to 50
ppm As in drinking water. No significant differences in AAS signals were measured in
mixtures containing 1% NaBH4 and 0.2 M to 1 M Tris, even though the pH measured after
the HG reaction decreased from 8.3 to 6.9 (Fig. 2). Similarly, changing NaBH4
concentration (0.5% to 2.5%) in a reaction mixture containing 0.75 M Tris had little effect
on the HG efficiency (Fig. 3).
Thus, each of the experimental parameters we examined exhibits a relatively broad
optimum, which is important for achieving robust and reliable analytical conditions. Based
†Electronic supplementary information (ESI) available: A scheme of the optimized HG-CT-AAS instrumentation and additional data
on stability of DMAsIII in cell lysates. See DOI: 10.1039/c1mt00095k
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on these results, we concluded that the 1 hour treatment with 2% cysteine and the HG
mixture containing 0.75 M Tris and 1% NaBH4 is optimal for analysis of liver homogenates.
Notably, the same reaction conditions were previously used in our laboratories for analyses
of liquid samples.26,30 To examine As recoveries under these conditions, additional aliquots
of the homogenates were analyzed after digestion in phosphoric acid. The analysis of acid-
digested homogenates showed that the direct analysis of the homogenates treated with 2%
cysteine recovered ~100% of MAsIIIIII + V and DMAsIII + V. Consistent with our previous
report,27 the average recovery of iAsIII + V was lower, reaching only about 85%.
The 1 hour treatment with 2% cysteine and the HG mixture containing 0.75 M Tris and 1%
NaBH4 was used in all following experiments examining the stability of trivalent arsenicals
in mouse liver homogenates and cell lysates.
Stability of trivalent arsenicals in mouse liver homogenates
The stability of AsIII species was examined in a 10% homogenate prepared from a liver of a
single mouse exposed to iAsIII in drinking water (50 ppm As) for 9 days. The homogenate
was prepared in ice-cold DIW and immediately aliquoted. Three freshly prepared aliquots
were analyzed directly for AsIII species; another 3 aliquots were pretreated with 2% cysteine
and analyzed for AsIII + V species. The AsIII + V species were also analyzed in acid digested
aliquots of the homogenate. To determine the stability of trivalent arsenicals, remaining
aliquots were stored at 0 °C (on ice) or −80 °C and analyzed for AsIII and AsIII + V species
after 1, 6, 13, and 22 days (Fig. 4).
In the fresh homogenate, trivalent arsenicals accounted for 65% of the sum of As species:
iAsIII (8%), MAsIII (12%), and DMAsIII (45%). However, the recovery of iAsIII + V was
only about 82% (Fig. 4A and B), suggesting that a part of iAs, possibly protein-bound iAsIII,
is not available for the HG reaction under these conditions. The recoveries of iAs remained
low for up to 13 days, but increased at day 22 for aliquots of the homogenate stored either at
0 °C (105%) or at −80 °C (113%) due to increased levels of iAsV. These data suggest that a
prolonged storage may result in the release of iAsIII from high-affinity binding sites,
followed by oxidation of iAsIII to iAsV. Notably, both MAsIII and DMAsIII were relatively
stable in aliquots of the homogenate stored at −80 °C for up to 22 days. Only about 18% of
MAsIII and 9% of DMAsIII oxidized under these conditions (Fig. 4C and E). In contrast,
42% of MAsIII and 88% of DMAsIII oxidized in aliquots of the homogenate stored at 0 °C
(Fig. 4D and F).
Generation and stability of DMAsIII in UROtsa/F35 cells
We have previously shown that cultured UROtsa/F35 cells treated with MAsIII produce
DMAsIII and DMAsV.28 In the present study, DMAsIII was generated in UROtsa/F35
culture exposed to 0.1 µM MAsIII (15 ng As per well) for 18 hours. DMAsIII levels were
monitored in the culture medium and in cell lysates that were prepared in ice-cold DIW. Fig.
5 shows that DMAsIII was the major product of MAsIII methylation and that a substantial
portion of DMAsIII was retained by cells. DMAsIII represented almost 50% and 90% of all
As species associated with the culture medium and cells, respectively. The stability of
DMAsIII was examined in both the medium and cell lysates prepared in DIW and stored at
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either 0 °C or −80 °C for up to 23 days. DMAsIII in cell lysates was stable regardless of the
storage temperature; DMAsIII in culture medium was stable only at −80 °C (Fig. 6). In
contrast, almost 50% of DMAsIII oxidized in the medium stored at 0 °C.
We also tested the stability of DMAsIII in cell lysates prepared in an ice-cold solution of
0.5% Triton X-100, a non-ionic laboratory detergent that is commonly used in biomedical
studies for sample processing. We found that fresh cell lysates prepared in Triton X-100
contained significantly less DMAsIII than the lysates prepared in DIW. The oxidation state
specific analysis showed that 54% of DMAsIII in these lysates oxidized to DMAsV (Fig. S2,
ESI†).
To assess the role of GSH in the stability of DMAsIII, UROtsa/F35 cells were incubated
with BSO for 24 hours and then exposed for 18 hours to MAsIII. The treatment with BSO
decreased the intracellular GSH concentration to 15% of the original level, but had no effect
on the stability of DMAsIII in cell lysates prepared in DIW and stored at either −80 °C or 0
°C (data not shown). Thus, it is possible that the remaining GSH provided sufficient
protection for DMAsIII in cell lysates or that DMAsIII was primarily bound to protein thiols
and could not be affected by BSO treatment.
Finally, we examined the stability of DMAsIII under conditions that are consistent with a
shipment of samples from field studies to analytical laboratories. Here, UROtsa/F35 cells
were exposed to 0.5 µM MAsIII (75 ng As per well) for 18 hours; aliquots of cell lysates
prepared in DIW and aliquots of culture medium were placed in two polystyrene shipping
containers filled with dry ice and two additional containers filled with ice packs that were
pre-frozen at −80 °C. One of the containers with dry ice and one with ice packs were stored
at UNC Chapel Hill and DMAsIII was analyzed in aliquots of the stored samples for up to 7
days. The other containers were shipped by an express postal service to Prague, Czech
Republic for analysis in the Institute of Analytical Chemistry. The HG-CT-AAS analysis at
UNC found that DMAsIII is stable in both cell lysates and media stored in dry ice for 2 days;
however, significant loses of DMAsIII occurred at day 5 and 7 (Fig. S3, ESI†). DMAsIII
oxidized faster in samples stored with ice packs. The shipment to Prague was delayed in
customs for 4 days, resulting in a significant oxidation of DMAsIII in culture medium and
cell lysates shipped in either dry ice or ice packs (Fig. S4, ESI†).
Conclusions
Previous work has shown that methylated trivalent metabolites of iAs, MAsIII and DMAsIII
are unstable in human urine.24 We have recently reported that up to 50% of DMAsIII can
oxidize during 24 hours even in urine stored in dry ice,39 making it difficult to detect and
quantify this metabolite in urine samples collected in population studies. The work presented
here confirms that the trivalent metabolites of iAs, iAsIII, MAsIII, and DMAsIII can be
detected and quantified in fresh cell lysates and tissue homogenates by direct HG-CT-AAS
analysis. The optimum conditions for analysis of the pentavalent arsenicals include the pre-
treatment with 2% cysteine for 60 minutes and generation of arsines in the reaction mixture
containing 1% NaBH4 and 0.75M Tris buffer (pH 6). Notably, the methylated trivalent
metabolites of iAs, including DMAsIII, are stable for at least 3 weeks in cell lysates and
Currier et al. Page 8






















tissue homogenates prepared in cold DIW and stored at −80 °C. When packed in dry ice,
these types of samples can be shipped without major losses of DMAsIII, as long as the
shipping time does not exceed 2 days and dry ice is not depleted during the shipment.
In summary, results of the present study suggest that, unlike urine, samples of tissues or
cells collected in human population studies provide suitable material for the quantitative,
oxidation state specific analysis of As species, assuming that these samples are properly
handled and stored prior to the analysis. Thus, while urine analysis helps to estimate the
levels of exposure to iAs and to evaluate the efficiency of iAs methylation, the analysis of
tissues or cells may provide important information about the internal dose and chemical
species of As, including highly toxic but unstable MAsIII and DMAsIII, in target tissues.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Peak areas recorded for iAsIII + V (A), MAsIII + V(B), and DMAsIII + V (C) during the direct
HG-CT-AAS analysis of aliquots of a mouse liver homogenate pre-treated with 0.5, 2, or
4% cysteine for up to 80 minutes. Time 0 minutes shows results of the direct analysis of
liver homogenates prior to the cysteine treatment. Each point represents a single
measurement.
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HG-CT-AAS analysis of pooled mouse liver homogenates pre-treated with 2% cysteine for
1 hour: effect of Tris buffer concentration in the HG reaction mixture on AAS signals for
iAsIII + V MAsIII + V, and DMAsIII + V. Each point represents mean ± SD for n = 3.
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HG-CT-AAS analysis of pooled mouse liver homogenates pre-treated with 2% cysteine for
1 hour: effect of NaBH4 concentration in the HG reaction mixture on AAS signals for
iAsIII + V, MAsIII + V,, and DMAsIII + V,. Each point represents mean ± SD for n = 3.
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Stability of trivalent arsenicals in a liver homogenate from a mouse exposed to iAsIII in
drinking water (50 ppm As) for 9 days: liver homogenate was prepared in DIW. The direct
HG-CT-AAS analysis was used to determine the concentrations of iAs (A, B), MAs (C, D)
and DMAs (E, F) species in aliquots of the fresh homogenate and in aliquots stored at −80
°C (A, C, E) or 0 °C (B, D, F) for up to 22 days (mean ± SD, n = 3). To control for As
recoveries during the direct analyses, iAsIII + V, MAsIII + V, and DMAsIII + V were
determined in aliquots of the fresh homogenate digested in phosphoric acid (mean, n = 3).
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*The concentration is significantly different from that found in the fresh homogenate (p <
0.01).
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Generation of DMAsIII in UROtsa/F35 culture exposed to 0.1 µM MAsIII (15 ng As per
well) for up to 18 hours. Tri- and pentavalent As species were measured by HG-CT-AAS in
culture medium (A) and cell lysates (B) before and after pretreatment with 2% cysteine
(mean ± SD, n = 3).
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Stability of DMAsIII in medium and cell lysates from UROtsa/F35 culture exposed to 0.1
µM MAsIII (15 ng As per well) for 18 hours: DMAsIII and DMAsV were analyzed in culture
medium (A, B) and cell lysates (C, D) immediately after the exposure and after storage at
−80 °C or 0 °C for up to 23 days (mean ± SD, n = 3). *The concentration is significantly
different from that found in fresh medium or cell lysate (p < 0.01).
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